Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations.


Journal

Lupus science & medicine
ISSN: 2053-8790
Titre abrégé: Lupus Sci Med
Pays: England
ID NLM: 101633705

Informations de publication

Date de publication:
07 2020
Historique:
received: 23 03 2020
revised: 03 06 2020
accepted: 04 06 2020
entrez: 4 7 2020
pubmed: 4 7 2020
medline: 11 5 2021
Statut: ppublish

Résumé

Systemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. Neutropaenia is a frequent event in SLE occurring in 20%-40% of patients depending on the threshold value of neutrophil count. On a daily basis, the management of neutropaenia in SLE is difficult with several possible causes. Moreover, the infectious consequences of neutropaenia in SLE remain not well defined. 998 patients from the Lupus BioBank of the upper Rhein (LBBR), a large German and French cohort of patients with SLE, mostly of Caucasian origin (83%), were included in this study. Neutropaenia was considered when neutrophil count was below 1800×10 208 patients with neutropaenia (21%) were compared with 779 SLE patients without neutropaenia. Neutropaenia in SLE was significantly associated with thrombocytopaenia (OR 4.11 (2.57-10.3)), lymphopaenia (OR 4.41 (2.51-11.5)) and low C3 (OR 1.91 (1.03-4.37)) in multivariate analysis. 65 representative patients with neutropaenia were analysed. Neutropaenia was moderate to severe in 38%, chronic in 31%, and both severe and chronic in 23% of cases. Moderate to severe and chronic neutropaenia were both associated with lymphopaenia and thrombopaenia. Chronic neutropaenia was also associated anti-Ro/SSA antibodies and moderate to severe neutropaenia with oral ulcers. This study is to date the largest cohort to describe neutropaenia in SLE. Neutropaenia displays a strong association with other cytopaenias, suggesting a common mechanism. Chronic neutropaenia is associated with anti-Ro/SSA antibodies with or without identified Sjögren's disease.

Identifiants

pubmed: 32616563
pii: 7/1/e000399
doi: 10.1136/lupus-2020-000399
pmc: PMC7333801
pii:
doi:

Substances chimiques

Antibodies, Antinuclear 0
Complement C3 0
SS-A antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Z Amoura (Z)
L Arnaud (L)
G Blaison (G)
B Bonnotte (B)
E Chatelus (E)
E Ciobanu (E)
F Duchene (F)
J P Faller (JP)
A Gorse (A)
J E Gottenberg (JE)
O Hinschberger (O)
F Jaeger (F)
P Kieffer (P)
M Kilifa (M)
N Magy-Bertrand (N)
T Martin (T)
L Martzolff (L)
F Maurier (F)
A Meyer (A)
J-L Pasquali (JL)
J-L Pennaforte (JL)
V Poindron (V)
S Revuz (S)
M Samson (M)
J Sibilia (J)
C Sordet (C)
A Theulin (A)
D Wahl (D)
J C Weber (JC)
M Bartsch (M)
N Bartholomä (N)
C Fiehn (C)
S Finzel (S)
A Funkert (A)
M Hausberg (M)
H Lorenz (H)
R Max (R)
H-H Peter (HH)
M Rizzi (M)
A Schwarting (A)
J Thiel (J)
N Venhoff (N)
R Voll (R)

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Medicine (Baltimore). 2004 Jan;83(1):1-17
pubmed: 14747764
Blood Rev. 2019 Sep;37:100586
pubmed: 31255364
Hematology. 2007 Jun;12(3):257-61
pubmed: 17558704
Ann Rheum Dis. 2014 Dec;73(12):2199-207
pubmed: 24013727
Arthritis Rheum. 1978 Apr;21(3):295-305
pubmed: 646828
Lupus. 2017 May;26(6):640-645
pubmed: 27760809
Arthritis Rheum. 2001 Oct;44(10):2350-7
pubmed: 11665976
Ann N Y Acad Sci. 2009 Sep;1173:103-7
pubmed: 19758138
Lupus. 1997;6(3):248-53
pubmed: 9104731
Cell. 2016 Apr 21;165(3):551-65
pubmed: 27040498
Semin Arthritis Rheum. 2015 Oct;45(2):190-4
pubmed: 26170228
Medicine (Baltimore). 1993 Mar;72(2):113-24
pubmed: 8479324
Clin Exp Immunol. 2000 Apr;120(1):209-17
pubmed: 10759785
Q J Med. 1991 Jul;80(291):605-12
pubmed: 1946940
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603

Auteurs

Aurore Meyer (A)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France.
UFR Médecine, Université de Strasbourg, Strasbourg, France.

Aurélien Guffroy (A)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France aurelien.guffroy@chru-strasbourg.fr.
UFR Médecine, Université de Strasbourg, Strasbourg, France.
INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Gilles Blaison (G)

Department of Internal Medicine, Hôpitaux Civils de Colmar, Colmar, Alsace, France.

Yannick Dieudonne (Y)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France.
UFR Médecine, Université de Strasbourg, Strasbourg, France.
INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Zahir Amoura (Z)

Department of Internal Medicine, Institut E3M, Assistance Publique Hôpitaux de Paris (APHP), Groupement Hospitalier Pitié Salpêtrière, Paris, France.

Bernard Bonnotte (B)

Department of Clinical Immunology and Internal Medicine, CHU Dijon Bourgogne, Dijon, France.

Christoph Fiehn (C)

ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany.

Pierre Kieffer (P)

Department of Internal Medicine, Centre hospitalier de Mulhouse, Mulhouse, France.

Hannes Martin Lorenz (HM)

Department of Medicine V, University Hospital Heidelberg, Center for Rheumatic Diseases Baden-Baden, Heidelberg, Germany.

Nadine Magy-Bertrand (N)

Department of Internal Medicine, CHU de Besançon, Besançon, France.

François Maurier (F)

Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France.

Jean-Louis Pennaforte (JL)

Department of Internal Medicine, CHU de Reims, Hôpital Robert Debré, Reims, France.

Hans-Hartmut Peter (HH)

Department of Rheumatology and Clinical Immunology, Medical Center - Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Andreas Schwarting (A)

Department of Internal Medicine, Universitätsmedizin, Mainz, Germany.

Jean Sibilia (J)

Department of Rheumatology, National Reference Center for autoimmune diseases (RESO), Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Laurent Arnaud (L)

UFR Médecine, Université de Strasbourg, Strasbourg, France.
INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Department of Rheumatology, National Reference Center for autoimmune diseases (RESO), Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Thierry Martin (T)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France.
UFR Médecine, Université de Strasbourg, Strasbourg, France.
INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Reinhard Edmund Voll (RE)

Department of Rheumatology and Clinical Immunology, Medical Center - Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Anne-Sophie Korganow (AS)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France.
UFR Médecine, Université de Strasbourg, Strasbourg, France.
INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH